Healthcare resource utilization among patients diagnosed with idiopathic pulmonary fibrosis in the United States

Journal of Medical Economics

Volumn 18, Issue 4, 2015, Pages 249-257

  Wu, Ning ^a   Yu, Yanni F ^b   Chuang, Chien Chia ^a   Wang, Rosa ^a   Benjamin, Nicole N ^a   Coultas, David B ^c  

^a EVIDERA   (United States)

^b BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

^c VETERANS AFFAIRS PORTLAND HEALTH CARE SYSTEM   (United States)

Author keywords

Comorbidity; Economic burden; Healthcare resource utilization; Idiopathic pulmonary fibrosis; Retrospective observational study

Indexed keywords

AGED; ARTICLE; CLINICAL ASSESSMENT; COMORBIDITY; COMPUTER ASSISTED TOMOGRAPHY; CONSUMER; DEMOGRAPHY; EMERGENCY WARD; FEMALE; FIBROSING ALVEOLITIS; FOLLOW UP; HEALTH CARE UTILIZATION; HEALTH MAINTENANCE ORGANIZATION; HOSPITALIZATION; HUMAN; HUMAN TISSUE; LUNG BIOPSY; MAJOR CLINICAL STUDY; MALE; MEDICAID; MEDICARE; OUTPATIENT; PREFERRED PROVIDER ORGANIZATION; RETROSPECTIVE STUDY; UNITED STATES; CLASSIFICATION; COST OF ILLNESS; ECONOMICS; HEALTH CARE PLANNING; HEALTH INSURANCE; INSURANCE; UTILIZATION;

AGED; COMORBIDITY; COST OF ILLNESS; FEMALE; HEALTH RESOURCES; HUMANS; IDIOPATHIC PULMONARY FIBROSIS; INSURANCE CLAIM REVIEW; INSURANCE, HEALTH; MALE; UNITED STATES;

EID: 84928571609     PISSN: 13696998     EISSN: 1941837X     Source Type: Journal    
DOI: 10.3111/13696998.2014.991789     Document Type: Article

References (20)

1. Mapel DW, Hunt WC, Utton R, et al. Idiopathic pulmonary fibrosis: survival in population based and hospital based cohorts. Thorax 1998;53:469-76
2. Gulati M. Diagnostic assessment of patients with interstitial lung disease. Prim Care Respir J 2011;20:120-7
3. Raghu G, Collard HR, Anstrom KJ, et al. Idiopathic pulmonary fibrosis: clinically meaningful primary endpoints in phase 3 clinical trials. Am J Respir Crit Care Med 2012;185:1044-8
4. Bandeira CD, Rubin AS, Cardoso PF, et al. Prevalence of gastroesophageal reflux disease in patients with idiopathic pulmonary fibrosis. J Bras Pneumol 2009;35:1182-9
5. Chung MJ, Goo JM, Im JG. Pulmonary tuberculosis in patients with idiopathic pulmonary fibrosis. Eur J Radiol 2004;52:175-9
6. Lettieri CJ, Nathan SD, Barnett SD, et al. Prevalence and outcomes of pulmonary arterial hypertension in advanced idiopathic pulmonary fibrosis. Chest 2006;129:746-52
7. Nathan SD, Basavaraj A, Reichner C, et al. Prevalence and impact of coronary artery disease in idiopathic pulmonary fibrosis. Respir Med 2010;104:1035-41
8. Ozawa Y, Suda T, Naito T, et al. Cumulative incidence of and predictive factors for lung cancer in IPF. Respirology 2009;14:723-8
9. Lancaster LH, Mason WR, Parnell JA, et al. Obstructive sleep apnea is common in idiopathic pulmonary fibrosis. Chest 2009;136:772-8
10. Fernandez Perez ER, Daniels CE, Schroeder DR, et al. Incidence, prevalence, and clinical course of idiopathic pulmonary fibrosis: a population-based study. Chest 2010;137:129-37
11. Nalysnyk L, Cid-Ruzafa J, Rotella P, et al. Incidence and prevalence of idiopathic pulmonary fibrosis: review of the literature. Eur Respir Rev 2012;21:355-61
12. Raghu G, Collard HR, Egan JJ, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 2011;183:788-824
13. King Jr. TE, Albera C, Bradford WZ, et al. All-cause mortality rate in patients with idiopathic pulmonary fibrosis. Implications for the design and execution of clinical trials. Am J Respir Crit Care Med 2014;189:825-31
14. Collard HR, Ward AJ, Lanes S, et al. Burden of illness in idiopathic pulmonary fibrosis. J Med Econ 2012;15:829-35
15. Navaratnam V, Fogarty AW, Glendening R, et al. The increasing secondary care burden of idiopathic pulmonary fibrosis: hospital admission trends in England from 1998 to 2010. Chest 2013;143:1078-84
16. Zhu B, Kulkarni PM, Stensland MD, et al. Medication patterns and costs associated with olanzapine and other atypical antipsychotics in the treatment of bipolar disorder. Curr Med Res Opin 2007;23:2805-14
17. Baser O, Chalk M, Fiellin DA, et al. Cost and utilization outcomes of opioiddependence treatments. Am J Manag Care 2011;17(Suppl 8):S235-48
18. Janes H, Pepe M. The optimal ratio of cases to controls for estimating the classification accuracy of a biomarker. Biostatistics 2006;7:456-68
19. Brown AW, Fischer CP, Shlobin OA, et al. Outcomes after hospitalization in idiopathic pulmonary fibrosis: a cohort study. Chest 2015;147:173-9. doi: 10.1378/chest.13-2424
20. Raghu G, Weycker D, Edelsberg J, et al. Incidence and prevalence of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2006;174:810-16